Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...

Across the recent three months, 6 analysts have shared their insights on Intellia Therapeutics (NASDAQ:NTLA), expressing a variety of opinions spanning from bullish to bearish. The table below ...

SAN DIEGO, Feb. 26, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Intellia Therapeutics (NTLA) with a Buy rating and $30 price target Intellia is a gene editing company developing medicines that ...

Intellia’s Q4 EPS beat expectations by $0.07. Revenue exceeded forecasts by $3.59 million. Stock price increased by 5.56% in pre-market trading. Cash reserves stand at $861.7 million, funding ...

Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was ...